<p>The powerful suppressive capabilities of regulatory T (T<sub>reg</sub>) cells and their appreciable contribution to tumour progression make them attractive immunotherapeutic targets. However, their role in systemic immune homeostasis makes it important to find ways to specifically target tumour-infiltrating T<sub>reg</sub> cells while leaving the wider system unperturbed. It is also unknown whether therapies depleting or disrupting the function of tumour-infiltrating T<sub>reg</sub> cells will provide the greatest efficacy while limiting immune-related adverse events. In addition, T<sub>reg</sub> cells share much of their biology with conventional CD4<sup>+</sup> T cells, introducing challenges when designing targeted immunotherapies. In this Review, we discuss recent advances in differentiating tumour-infiltrating T<sub>reg</sub> cells from their systemic and tissue-resident counterparts and understanding how the biology of tumour-infiltrating T<sub>reg</sub> cells differs from conventional CD4<sup>+</sup> T cells. We also discuss how recent technological advances may enable the study of tumour-infiltrating T<sub>reg</sub> cells in even greater detail, helping to identify new targets for next-generation immunotherapeutic drugs.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Regulatory T cells in the tumour microenvironment

  • Charlotte J. Imianowski,
  • Qiang Chen,
  • Creg J. Workman,
  • Dario A. A. Vignali

摘要

The powerful suppressive capabilities of regulatory T (Treg) cells and their appreciable contribution to tumour progression make them attractive immunotherapeutic targets. However, their role in systemic immune homeostasis makes it important to find ways to specifically target tumour-infiltrating Treg cells while leaving the wider system unperturbed. It is also unknown whether therapies depleting or disrupting the function of tumour-infiltrating Treg cells will provide the greatest efficacy while limiting immune-related adverse events. In addition, Treg cells share much of their biology with conventional CD4+ T cells, introducing challenges when designing targeted immunotherapies. In this Review, we discuss recent advances in differentiating tumour-infiltrating Treg cells from their systemic and tissue-resident counterparts and understanding how the biology of tumour-infiltrating Treg cells differs from conventional CD4+ T cells. We also discuss how recent technological advances may enable the study of tumour-infiltrating Treg cells in even greater detail, helping to identify new targets for next-generation immunotherapeutic drugs.